Zechendorf Elisabeth, Schröder Katharina, Stiehler Lara, Frank Nadine, Beckers Christian, Kraemer Sandra, Dreher Michael, Kersten Alexander, Thiemermann Christoph, Marx Gernot, Simon Tim-Philipp, Martin Lukas
Department of Intensive and Intermediate Care, University Hospital RWTH Aachen, 52074 Aachen, Germany.
Department of Pneumology and Intensive Care Medicine, University Hospital RWTH Aachen, 52074 Aachen, Germany.
J Clin Med. 2022 Sep 6;11(18):5261. doi: 10.3390/jcm11185261.
SARS-CoV-2 was first detected in 2019 in Wuhan, China. It has been found to be the most pathogenic virus among coronaviruses and is associated with endothelial damage resulting in respiratory failure. Determine whether heparanase and heparan sulfate fragments, biomarkers of endothelial function, can assist in the risk stratification and clinical management of critically ill COVID-19 patients admitted to the intensive care unit. We investigated 53 critically ill patients with severe COVID-19 admitted between March and April 2020 to the University Hospital RWTH Aachen. Heparanase activity and serum levels of both heparanase and heparan sulfate were measured on day one (day of diagnosis) and day three in patients with COVID-19. The patients were classified into four groups according to the severity of ARDS. When compared to baseline data (day one), heparanase activity increased and the heparan sulfate serum levels decreased with increasing severity of ARDS. The heparanase activity significantly correlated with the lactate concentration on day one ( = 0.34, = 0.024) and on day three ( = 0.43, = 0.006). Heparanase activity and heparan sulfate levels correlate with COVID-19 disease severity and outcome. Both biomarkers might be helpful in predicting clinical course and outcomes in COVID-19 patients.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）于2019年在中国武汉首次被发现。它是冠状病毒中致病性最强的病毒，与导致呼吸衰竭的内皮损伤有关。确定作为内皮功能生物标志物的乙酰肝素酶和硫酸乙酰肝素片段是否有助于对入住重症监护病房的重症2019冠状病毒病（COVID-19）患者进行风险分层和临床管理。我们调查了2020年3月至4月间收治于亚琛工业大学医院的53例重症COVID-19患者。在COVID-19患者确诊当天（第1天）和第3天测量乙酰肝素酶活性以及乙酰肝素酶和硫酸乙酰肝素的血清水平。根据急性呼吸窘迫综合征（ARDS）的严重程度将患者分为四组。与基线数据（第1天）相比，随着ARDS严重程度的增加，乙酰肝素酶活性升高，硫酸乙酰肝素血清水平降低。乙酰肝素酶活性在第1天（r = 0.34，P = 0.024）和第3天（r = 0.43，P = 0.006）与乳酸浓度显著相关。乙酰肝素酶活性和硫酸乙酰肝素水平与COVID-19疾病的严重程度和预后相关。这两种生物标志物可能有助于预测COVID-19患者的临床病程和预后。
